Skip to main content
. 2018 Sep 26;25(3):610–619. doi: 10.1093/ibd/izy291

TABLE 3A.

Distribution of CDI Severity and 1-Year Adverse Outcomes by CDI Treatment for Patients with Crohn’s Disease (n = 63)*

No Treatment Vanco Metro Both Both+Rifa N P Value
CDI severity
 Moderate 1 (2) 11 (24) 20 (44) 13 (29) 0 (0) 45 .40
 Severe 0 (0) 1 (13) 3 (38) 4 (50) 0 (0) 8
 Severe-complicated 0 (0) 0 (0) 4 (40) 6 (60) 0 (0) 10
Subsequent CDI 63 .54
 No 1 (2) 7 (11) 21 (33) 15 (24) 0 (0)
 Yes 0 (0) 5 (8) 6 (10) 8 (13) 0 (0)
Recurrent CDI 63 .63
 No 1 (2) 11 (17) 24 (38) 18 (29) 0 (0)
 Yes 0 (0) 1 (2) 3 (5) 5 (8) 0 (0)
CDI-related hospitalization 63 .20
 No 1 (2) 10 (16) 24 (38) 23 (37) 0 (0)
 Yes 0 (0) 2 (3) 3 (5) 0 (0) 0 (0)
IBD exacerbation 63 .38
 No 1 (2) 7 (11) 12 (19) 8 (13) 0 (0)
 Yes 0 (0) 5 (8) 15 (24) 15 (24) 0 (0)
Colon Surgery 63 .11
 No 1 (2) 8 (13) 23 (37) 13 (21) 0 (0)
 Yes 0 (0) 4 (6) 4 (6) 10 (16) 0 (0)

Abbreviations: both, vancomycin plus metronidazole; both+rifa, vancomycin plus metronidazole plus rifaximin; metro, metronidazole only; vanco, vancomycin only.

*Data are presented as No. (%).

Fisher exact test.